AUS
NZ
UK
CA
USA
IND
Suda pharmaceuticals ltd asx sud
SUDA Secures Australian Patent Office’s Approval on Anagrelide Cancer Patent
September 09, 2020 02:17 PM AEST| By Team Kalkine MediaSummary SUDA’s share price soared by ~12% on securing approval for anagrelide cancer patent in Australia. With the Australian Patent Office accepting the patent application, the anagrelide patent will now proceed to grant. The approval o.....
Scan Through SUDA’s Key Operational Achievements in FY 2019-2020
August 31, 2020 08:29 PM AEST| By Team Kalkine MediaSummary SUDA reported key operational achievements for FY 2019-2020. The Company finalised a key agreement with Cann Pharma Australia during the year. The financial year also saw the signing of three significant agreements with Sanofi, Ordesa .....
SUDA Closed Entitlement Offer Substantially Oversubscribed, Reported June 2020 Qtr Achievements
August 05, 2020 08:35 PM AEST| By Team Kalkine MediaSummary SUDA’s Entitlement Offer to raise ~$3.56 million has been strongly supported by its shareholders and closed substantially oversubscribed. The Company will now issue ~142.25 million shares and 47.4 million listed options in line wi.....
Whitefield Industrials (ASX:WHF) Shares in Focus Amid Broader Market Evaluation
July 20, 2026 11:57 AM AEST| By Aditi SarkarWhitefield Industrials Ltd (ASX: WHF) ended trading on 20 July 2026 at AUD 4.76, representing a 1.86% decline for the session. Although the stock moved lower on the day, its performance should be viewed within a broader context, with the company remaining down 16.05% …
SUDA Reaches Major Milestone with Grant of TGA Approval for ZolpiMistTM, Stock Rallies Above 150%
July 30, 2020 12:00 AM AEST| By Team Kalkine MediaSUDA Pharmaceuticals Limited (ASX:SUD) soared above 150 per cent to $0.068 on ASX on 29 July 2020, following the announcement regarding grant of Therapeutics Goods Administration’s (TGA) approval for ZolpiMistTM (zolpidem tartrate). Notably, .....
SUDA Seeking Participation in $3.56M Capital Raising, Eyeing development of Anagrelide and OroMist Assets
July 23, 2020 08:10 PM AEST| By Team Kalkine MediaSUDA Pharmaceuticals Limited (ASX:SUD), the global leader in reformulating and delivering medication via the oral mucosa is seeking shareholders’ support to participate in the capital raising activity announced in early July 2020. On 3rd Jul.....
SUDA Announces $3.56 Million Capital Raising to Fund Development of its Key Assets
July 06, 2020 11:28 AM AEST| By Team Kalkine MediaAustralia’s oro-mucosal drug delivery leader, SUDA Pharmaceuticals Limited (ASX:SUD) has recently announced a non-renounceable entitlement offer to raise about $3.56 million via issue of ~142 million new ordinary shares in SUDA, at an attract.....
Woodside Energy (ASX:WDS) Shares Rise as Middle East Tensions Escalate
July 20, 2026 10:08 AM AEST| By Sonal GoyalWoodside Energy Group Limited (ASX:WDS) began the week on the front foot as crude oil surged and investors rushed back into energy names. The catalyst was geopolitical: reports described a fresh escalation in hostilities between the United States and Iran over the weekend, alongside …
SUDA Reports Significant Preliminary Results from Anagrelide Pharmacokinetic Study
May 28, 2020 05:07 PM AEST| By Team Kalkine MediaSummary SUDA made further progress towards Anagrelide program, attaining significant preliminary results from a pharmacokinetic study. Results support SUDA’s hypothesis that Anagrelide’s mouth spray formulation can lessen the risk o.....
Japanese Patent Office Accepted SUDA’s Anagrelide Cancer Patent Application; Stock Surged Over 10%
May 21, 2020 12:29 PM AEST| By Team Kalkine MediaThe Japanese Patent Office has accepted Anagrelide cancer patent application, and the patent would now proceed to grant, notified SUDA Pharmaceuticals Ltd (ASX:SUD) in its latest update. The patent “Use of Anagrelide for Treating Cancer”...
SUDA Expects TGA Review Completion for ZolpiMist™ by Q4 2020
May 14, 2020 12:52 PM AEST| By Team Kalkine MediaSUDA Pharmaceuticals Limited (ASX:SUD), an Australia-based oro-mucosal drug delivery player, notified in its latest update that the Therapeutic Goods Administration (TGA) review for its insomnia drug ZolpiMistTM is expected to be completed by Q4 2020...
BHP (ASX:BHP) Attempts Comeback After Heavy Selling---Has the Mining Giant Found Its Floor?
July 20, 2026 09:49 AM AEST| By Sonal GoyalBHP describes itself as the world's largest copper producer and operates across three core pillars, plus steelmaking coal. The first pillar is iron ore, anchored by its low-cost Western Australia Iron Ore (WAIO) operations in the Pilbara plus a stake in Brazil's Samarco joint …
SUDA’s March Quarter Report Card Out! Let’s Browse Through Key Developments
May 04, 2020 11:55 AM AEST| By Team Kalkine MediaOro-mucosal drug delivery company, SUDA Pharmaceuticals Limited (ASX:SUD) has announced another set of robust quarterly results for the third quarter of FY2020. During the period, the Company made considerable progress in line with the 2020 targets h...
SUDA Pharmaceuticals Discovering Use of Anagrelide as Adjuvant Therapy in Treating Cancer
April 17, 2020 03:03 PM AEST| By Team Kalkine MediaPills, capsules, and tablets may not be the most efficient method for administering medicines as only ~10 – 30 per cent of the drug reaches the bloodstream. Several factors, including food effect, enzymatic degradation and first-pass metabolism...
SUDA Sets Out Steps in Response to COVID-19 Pandemic
April 01, 2020 04:03 PM AEDT| By Team Kalkine MediaIn a recent letter to its top shareholders, Perth-based oro-mucosal drug delivery company SUDA Pharmaceuticals Ltd (ASX:SUD) has outlined the steps it is taking amidst COVID-19 pandemic, that has so far infected more than 780,000 people and claimed l...
Coles Group (ASX:COL) Walks Away From the $4 Billion Greencross Deal After Investor Backlash
July 20, 2026 09:49 AM AEST| By Sonal GoyalColes Group Limited (ASX:COL) has stepped back from the largest acquisition it has ever contemplated, confirming in mid-July 2026 that it had ceased discussions to buy pet-care group Greencross. Multiple outlets reported the transaction as worth more than A$4 billion including debt, the same …
SUDA Continues With its Commercial Buildout of ZolpiMist™, Signed Additional Licence for the product with Mitsubishi Tanabe Pharma Korea
March 24, 2020 08:40 PM AEDT| By Team Kalkine MediaProgressing remarkably with the commercialisation of its insomnia drug ZolpiMistTM, the oro-mucosal drug delivery leader SUDA Pharmaceuticals Limited (ASX:SUD) has signed an additional licence agreement with one of the top Japanese pharmaceutical com...
Lens over SUDA’s Operational Highlights in 1H FY20
March 04, 2020 01:59 PM AEDT| By Hina ChowdharyContinuing its practice of delivering solid operational results, oro-mucosal drug delivery firm SUDA Pharmaceuticals Ltd (ASX:SUD) has recently declared results for the half-year period ended 31st December 2019. The Company continued to focus on attr...
SUDA Delivered Strong Performance in 2Q FY20, A Glimpse of Operational Highlights
February 05, 2020 02:23 PM AEDT| By Team Kalkine MediaContinuing its practice of making robust quarterly progress, the oro-mucosal drug delivery player of Australia, SUDA Pharmaceuticals Limited (ASX: SUD) is out with another solid quarterly report for the December 2019 quarter. SUDA is a world leader...
Deep Yellow (ASX:DYL) Awards $34 Million of Tumas Contracts as a Major Uranium Decision Moves Closer
July 20, 2026 09:49 AM AEST| By Sonal GoyalDeep Yellow Limited told the market on 20 July 2026 it had awarded two construction packages worth a combined roughly A$34 million for the Tumas uranium project in Namibia. The recipients are two fully Namibian-owned firms: Namibia Construction, valued at about A$18.5 million, and …
SUDA Pharmaceuticals Signed Two Major Deals with Sanofi and Ordesa
January 21, 2020 06:34 PM AEDT| By Team Kalkine MediaIn a significant development, Australia-based pharmaceutical player SUDA Pharmaceuticals Limited (ASX: SUD) has recently signed deals with two renowned entities - Sanofi Aventis Groupe and Laboratorios Ordesa S.L. The deals followed the agreement fi...
SUDA Pharmaceuticals Proposed Share Consolidation for Effective Capital Structure
October 17, 2019 06:20 PM AEDT| By Team Kalkine MediaBased in the United States and Australia, SUDA Pharmaceuticals Ltd (ASX: SUD) is a leading drug delivery company of the world engaged in the reformulation of existing medications and delivery of drugs via the oral mucosa. To reformulate the existing...
SUDA Prospers Via Drug Delivery Partnerships: A Quick Review of Deals Transacted for ZolpiMistTM
October 09, 2019 01:31 PM AEDT| By Team Kalkine MediaOro-mucosal drug delivery giant, SUDA Pharmaceuticals Limited (ASX: SUD) is engaged in the pharmaceutical development of drug delivery technology. To increase bioavailability, the company is reformulating the existing drugs into oral sprays. The comp...
EQ Resources (ASX:EQR): Andrew Forrest's $190 Million Tungsten Bet Sends This ASX Critical-Minerals Stock Soaring
July 20, 2026 09:49 AM AEST| By Sonal GoyalEQ Resources Limited (ASX:EQR) has become one of the most talked-about names on the ASX after reports that Andrew Forrest, the billionaire behind Fortescue, has built a commanding position on its register. According to the reporting, Forrest has taken a personal stake of about …
Insight into Oro-Mucosal Drug Delivery Leader, SUDA Pharmaceutical’s FY19 Annual Report
September 27, 2019 05:58 PM AEST| By Team Kalkine MediaAustralian-headquartered global pharmaceutical leader, SUDA Pharmaceuticals Limited (ASX: SUD) is engaged in the reformulation of existing drugs and provision of medication via the oral mucosa. The company uses its exclusive OroMist? technology to cr...
SUDA Pharmaceuticals Progressing Well in 2019 with Significant Regulatory and Patent Approvals
September 20, 2019 01:02 PM AEST| By Team Kalkine MediaAustralia?s leading oro-mucosal drug delivery company, SUDA Pharmaceuticals Ltd (ASX: SUD) develops low-risk, easy-to-use oral sprays using its OroMist? technology to reformulate existing medications. The company?s oral-delivery technology is not onl...
Advertise your brand on Kalkine Media